No Data
No Data
Rallybio to Present at the 2024 Jones Healthcare Seaside Summit
NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with
TD Cowen Maintains Rallybio(RLYB.US) With Buy Rating
TD Cowen analyst Ritu Baral maintains $Rallybio(RLYB.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 43.5% and a total average return of 7.4% over the past year.No
JMP Securities Maintains Rallybio(RLYB.US) With Buy Rating, Maintains Target Price $8
JMP Securities analyst Jonathan Wolleben maintains $Rallybio(RLYB.US)$ with a buy rating, and maintains the target price at $8.According to TipRanks data, the analyst has a success rate of 0.0% and a
Express News | Rallybio Corp: On Track to Initiate Rlyb212 Phase 2 Dose Confirmation Study in Pregnant Women at Higher Risk for Fnait in 2H 2024
Express News | Rallybio Corp: Topline Results Suggest Significant Increase in Number of Pregnancies at Higher Risk for Fnait Annually and Rlyb212 Addressable Market
Express News | Rallybio Announces Results of Epidemiological Analysis Demonstrating Fnait Risk Across Racially and Ethnically Diverse Populations
No Data